Posted in

Chemo Benefits in Stage I Ovarian Clear Cell Carcinoma

•Posted inObstetrics and Gynaecology

Ovarian clear cell carcinoma represents a unique subtype of epithelial ovarian cancer. Doctors frequently diagnose this condition at stage I. Consequently, the role of adjuvant chemotherapy remains a significant point of discussion in clinical practice. Recent data helps clarify the survival benefits for these patients.

Survival Benefits of Adjuvant Chemotherapy

Researchers recently conducted a comprehensive meta-analysis of nine studies. They found that chemotherapy significantly improves disease-free survival. Specifically, the treatment reduced the risk of recurrence by approximately 53%. Furthermore, the hazard ratio for overall survival was 0.66. This suggests a potential long-term benefit for many women. However, the absolute benefit varies greatly depending on the specific substage.

Ovarian Clear Cell Carcinoma Substage Treatment Benefits

The impact of Ovarian Clear Cell Carcinoma treatment depends heavily on the initial risk of recurrence. For instance, the estimated number needed to treat for stage I overall is 10.2. Stage IA patients show a much higher number needed to treat of 40.8. In contrast, the number for stage IC is only 5.2. This indicates that chemotherapy provides a much larger absolute benefit for stage IC disease. Consequently, physicians must weigh these risks against the potential side effects of treatment.

Frequently Asked Questions

Q1: Does adjuvant chemotherapy improve survival in stage I Ovarian Clear Cell Carcinoma?

Yes, meta-analysis data shows that chemotherapy reduces the risk of recurrence by roughly 50%. It also shows a trend toward improved overall survival.

Q2: Is the benefit the same for all stage I patients?

No, the benefit is much more pronounced in stage IC. Patients in stage IA have a very low baseline risk of recurrence. Therefore, the absolute benefit of chemotherapy for them is smaller.

References

  1. Inayama Y et al. Adjuvant Chemotherapy in Stage I Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-analysis. Obstet Gynecol. 2026 Mar 01. doi: 10.1097/AOG.0000000000006116. PMID: 41712944.
  2. Nasioudis D et al. Adjuvant chemotherapy for stage I ovarian clear cell carcinoma. Gynecol Oncol. 2019;153(2):337-342.
  3. Frontiers in Oncology. Impact of Adjuvant Chemotherapy on FIGO Stage I Ovarian Clear Cell Carcinoma. 2022.